Nouscom, with one major partner and strong confidence, is building research and manufacturing foundations to address significant market needs with its neoantigen cancer vaccine platform.
Marina Udier faces a challenging task as CEO of NousCom AG, a Basel, Switzerland-based biotech developing neoantigen-based vaccines.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.
